Figure 3.
Progression-free survival (PFS) and overall survival (OS) in treatment arms in TRIBE study according to G/G or any C PIN1 rs2233678 alleles: arm A receiving FOLFIRI + bevacizumab (irinotecan cohort 1); arm B receiving FOLFOXIRI + bevacizumab (combination cohort).